Cargando…
Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large‐cell lymphoma (sALCL) prior to autologous stem‐cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930222/ https://www.ncbi.nlm.nih.gov/pubmed/29744059 http://dx.doi.org/10.1002/ccr3.1461 |